Obesity and contraceptive use: impact on cardiovascular risk
Abstract Obesity and oestrogen containing contraceptive products are well‐known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative...
Main Authors: | Giuseppe M.C. Rosano, Maria Angeles Rodriguez‐Martinez, Ilaria Spoletini, Pedro Antonio Regidor |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-12-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.14104 |
Similar Items
-
Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience
by: Yong-Su Jang, et al.
Published: (2021-07-01) -
Comparison of risks of thromboembolism of drospirenone-containing and nondrospirenone -containing combined oral contraceptive use: A meta-analysis
by: Wan-Lin Zhang, et al.
Published: (2021-01-01) -
A Multi-Institutional Informed Consent Proposal as a Prevention Tool for Combined Oral Contraceptive Intake and Thrombotic Risk
by: Marina Vinciguerra, et al.
Published: (2023-03-01) -
Noncontraceptive effects of combined oral contraceptives: benefits and risks of use
by: A L Unanyan, et al.
Published: (2017-04-01) -
An oral combined contraceptive user with elevated D-dimer post COVID-19: a case report
by: Nada A. Alyousefi
Published: (2021-08-01)